Allan Goldstein
Pulmonary Disease · Birmingham, ALNPI 1316960248
Payments from drug & device makers
What this record shows
23 manufacturers reported payments, led by AstraZeneca at 52.6% of the total. Reporting peaked in 2019 at $2,218 and has fallen 99.0% since, to $22 in 2025. That places this record below the midpoint for pulmonary disease clinicians in AL, where the typical reported total is $3,082.
Across 86 payments — averaging $37.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Inspire Medical Systems, Inc.$321
- Electromed, Inc.$278
- Actelion Pharmaceuticals US, Inc.$177
- Genentech USA, Inc.$138
- Jazz Pharmaceuticals Inc.$117
- plus $488 from 17 others
What the payments were for
- Speaking & faculty fees$1,67552%
- Food & beverage$1,53148%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,206 in reported general payments places this provider in the 50th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$134K
- Amanda DenhamBirmingham$45K
- Bryan GarciaBirmingham$29K
- Steven RoweBirmingham$27K
- Peter MorrisBirmingham$25K
- Russell BeatyBirmingham$24K
- Jay HeideckerBirmingham$21K
- Jennifer TrevorBirmingham$19K
- Jason FainBirmingham$18K
- Jeffrey GarnerBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.